Summit Therapeutics (SMMT) Releases Financial Results and Updates on Operational Progress for Q3 2025

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the Stocks to Buy with Exponential Growth Heading into 2026. On October 20, the company released its financial results and gave an update on operational progress for Q3 2025. Summit Therapeutics Inc. (NASDAQ:SMMT) announced that, on the basis of the results of HARMONi clinical trial, it is planning to submit a Biologics License Application (BLA) to seek approval for ivonescimab plus chemotherapy for the proposed indication. Notably, the company plans to submit BLA in Q4 2025.

Summit Therapeutics Inc. (NASDAQ:SMMT) also announced that it intends to start HARMONi-GI3, which is a Phase III, multi-regional, clinical trial evaluating ivonescimab plus chemotherapy as compared to bevacizumab plus chemotherapy as the first line therapy in patients having unresectable metastatic colorectal cancer (CRC). Notably, the primary endpoint for this study is PFS, and Summit Therapeutics Inc. (NASDAQ:SMMT) expects to enroll 600 patients. In a separate release, on October 24, analyst David Dai of UBS maintained a “Buy” rating on the company’s stock, retaining the price objective of $30.00. The rating is backed by factors surrounding the promising results of the company’s HARMONi-6 trial.

While we acknowledge the potential of SMMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now

Disclosure: None. This article is originally published at Insider Monkey.